This is a routine medical conference data dump with no financial catalysts. ORLADEYO's core commercial story remains unchanged. Watch for Phase 3 navenibart (ALPHA-ORBIT) top-line data as the next binary catalyst — timing not stated in this release. No actionable trade signal from this filing alone.
Price Chart
Executive Summary
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained HAE attack reductions and a post hoc analysis of Phase 1b/2 navenibart data supporting ongoing Phase 3 evaluation. The press release contains no new revenue, earnings, or financial guidance — it is a clinical data update with routine positive framing.
Key Facts
- ORLADEYO 48-week data in pediatric HAE (APeX-P; n=29) showed median adjusted attack rate fell from 0.691/month (SOC) to 0.169/month on treatment.
- Attacks requiring professional care dropped from 22 (SOC 12wk) to 3 (first 12wk on ORLADEYO), reaching 0 in weeks 37-48.
- Phase 1b/2 ALPHA-STAR post hoc analysis (navenibart, n=29) showed consistent HAE attack reductions across baseline attack rate, BMI, and age subgroups.
- No severe or serious treatment-emergent adverse events reported for navenibart; most common TEAEs were headache, nasopharyngitis, and UTI.
- Multiple real-world evidence posters demonstrate ORLADEYO reduces healthcare utilization and improves patient satisfaction.
- No financial data, revenue, EPS, guidance, or material commercial updates were provided in this press release.
Financial Impact
No direct financial impact disclosed; clinical data updates support ongoing commercialization and pipeline value but do not change near-term revenue outlook for ORLADEYO.
Risk Factors
- No new commercial metrics or revenue guidance were provided — upside from this data is speculative.
- Navenibart Phase 3 results remain pending; could fail to replicate Phase 1b/2 findings in a larger, longer trial.
- Small n (29) and open-label design of APeX-P and ALPHA-STAR limit conclusiveness of these data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.14 (−10.25%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.14 (−14.76%) |
Jun 12, 2026 15w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.14 (−10.15%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.14 (−6.44%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.14 (−6.86%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.14 (−15.21%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.14 (−7.81%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.14 (−11.52%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.14 (−8.95%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.14 (−13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access